Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Determining a low disease activity threshold for decision to maintain disease-modifying antirheumatic drug treatment unchanged in rheumatoid arthritis patients.
de Bandt M, Fautrel B, Maillefert JF, Berthelot JM, Combe B, Flipo RM, Lioté F, Meyer O, Saraux A, Wendling D, Le Loët X, Guillemin F; STPR group of the French Society of Rheumatology. de Bandt M, et al. Arthritis Res Ther. 2009;11(5):R157. doi: 10.1186/ar2836. Epub 2009 Oct 23. Arthritis Res Ther. 2009. PMID: 19849865 Free PMC article.
Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
Fautrel B, Guillemin F, Meyer O, de Bandt M, Berthelot JM, Flipo RM, Lioté F, Maillefert JF, Wendling D, Saraux A, Combe B, Le Loët X; Stratégies Thérapeutiques dans La Polyarthrite RhumatoIde Working Group; Club Rhumatismes et Inflammation; French Society of Rheumatology. Fautrel B, et al. Among authors: de bandt m. Arthritis Rheum. 2009 Apr 15;61(4):425-34. doi: 10.1002/art.24588. Arthritis Rheum. 2009. PMID: 19333993 Free article.
Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology.
Le Loët X, Berthelot JM, Cantagrel A, Combe B, De Bandt M, Fautrel B, Flipo RM, Lioté F, Maillefert JF, Meyer O, Saraux A, Wendling D, Guillemin F. Le Loët X, et al. Among authors: de bandt m. Ann Rheum Dis. 2006 Jan;65(1):45-50. doi: 10.1136/ard.2005.035436. Epub 2005 Jun 30. Ann Rheum Dis. 2006. PMID: 15994280 Free PMC article.
A tool to identify recent or present rheumatoid arthritis flare from both patient and physician perspectives: the 'FLARE' instrument.
Berthelot JM, De Bandt M, Morel J, Benatig F, Constantin A, Gaudin P, Le Loet X, Maillefert JF, Meyer O, Pham T, Saraux A, Solau-Gervais E, Spitz E, Wendling D, Fautrel B, Guillemin F; STPR group of French Society of Rheumatology. Berthelot JM, et al. Among authors: de bandt m. Ann Rheum Dis. 2012 Jul;71(7):1110-6. doi: 10.1136/ard.2011.150656. Epub 2011 Nov 9. Ann Rheum Dis. 2012. PMID: 22072015
Validation of FLARE-RA, a Self-Administered Tool to Detect Recent or Current Rheumatoid Arthritis Flare.
Fautrel B, Morel J, Berthelot JM, Constantin A, De Bandt M, Gaudin P, Maillefert JF, Meyer O, Pham T, Saraux A, Solau-Gervais E, Vittecoq O, Wendling D, Erpelding ML, Guillemin F; STPR Group of the French Society of Rheumatology. Fautrel B, et al. Among authors: de bandt m. Arthritis Rheumatol. 2017 Feb;69(2):309-319. doi: 10.1002/art.39850. Arthritis Rheumatol. 2017. PMID: 27636400
Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6 months' first-line DMARD therapy.
Meyer O, de Bandt M, Berthelot JM, Cantagrel A, Combe B, Fautrel B, Flipo RM, Lioté F, Maillefert JF, Saraux A, Wendling D, Guillemin F, Le Loët X; Working Group for Therapeutic Strategies for Rheumatoid Arthritis. Meyer O, et al. Among authors: de bandt m. Joint Bone Spine. 2007 Jan;74(1):73-8. doi: 10.1016/j.jbspin.2006.05.008. Epub 2006 Nov 29. Joint Bone Spine. 2007. PMID: 17194614
131 results